These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20378025)

  • 1. Clinical outcome evaluation following cyclosporine a treatment in moderate to severe psoriasis: a retrospective study.
    Colombo D; Flori L; Altomare G; Aste N; Sgarbi S
    Int J Immunopathol Pharmacol; 2010; 23(1):363-7. PubMed ID: 20378025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study.
    Colombo D; Cassano N; Altomare G; Giannetti A; Vena GA
    Int J Immunopathol Pharmacol; 2010; 23(4):1143-52. PubMed ID: 21244763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis.
    Laburte C; Grossman R; Abi-Rached J; Abeywickrama KH; Dubertret L
    Br J Dermatol; 1994 Mar; 130(3):366-75. PubMed ID: 8148280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
    Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis.
    Erkko P; Granlund H; Nuutinen M; Reitamo S
    Br J Dermatol; 1997 Jan; 136(1):82-8. PubMed ID: 9039300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris.
    Abe M; Ishibuchi H; Syuto T; Sogabe Y; Yokoyama Y; Ishikawa O
    J Dermatol; 2007 May; 34(5):290-3. PubMed ID: 17408436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients.
    Okubo Y; Natsume S; Usui K; Amaya M; Tsuboi R
    J Dermatol; 2011 May; 38(5):465-72. PubMed ID: 21352289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between lymphocyte cyclosporin sensitivity and clinical progress of psoriasis.
    Umezawa Y; Oh-i T; Koga M
    J Dermatol Sci; 2001 Jun; 26(2):94-9. PubMed ID: 11378324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A.
    Schopf RE; Hultsch T; Lotz J; Bräutigam M
    J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):234-9. PubMed ID: 9883435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
    Berth-Jones J; Henderson CA; Munro CS; Rogers S; Chalmers RJ; Boffa MJ; Norris PG; Friedmann PS; Graham-Brown RA; Dowd PM; Marks R; Sumner MJ
    Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
    Peluso AM; Bardazzi F; Tosti A; Varotti C
    Acta Derm Venereol Suppl (Stockh); 1994; 186():90-1. PubMed ID: 8073851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis.
    Di Lernia V; Stingeni L; Boccaletti V; Calzavara Pinton PG; Guarneri C; Belloni Fortina A; Panzone M; Corazza M; Neri I; Cambiaghi S; Lasagni C; Ficarelli E; Gisondi P
    J Dermatolog Treat; 2016 Oct; 27(5):395-8. PubMed ID: 26571044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
    Yoon HS; Youn JI
    J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis.
    Ohtsuki M; Nakagawa H; Sugai J; Ozawa A; Ohkido M; Nakayama J; Hanada J; Morimoto Y; Jimbow K; Horikoshi T; Kitahara H; Tamaki K; Urabe K; Hori Y
    J Dermatol; 2003 Apr; 30(4):290-8. PubMed ID: 12707465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series.
    García-Bustínduy M; Escoda M; Guimerá FJ; Sáez M; Dorta S; Fagundo E; Sánchez-González R; Noda-Cabrera A; García-Montelongo R
    J Eur Acad Dermatol Venereol; 2004 Mar; 18(2):169-72. PubMed ID: 15009296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.
    Maza A; Montaudié H; Sbidian E; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP; Paul C
    J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():19-27. PubMed ID: 21388455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group.
    Koo J
    Br J Dermatol; 1998 Jul; 139(1):88-95. PubMed ID: 9764154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
    Touw CR; Hakkaart-Van Roijen L; Verboom P; Paul C; Rutten FF; Finlay AY
    Br J Dermatol; 2001 May; 144(5):967-72. PubMed ID: 11359382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.